Genitourinary Cancers | Specialty

Jim Feldman on the Importance of Social Networking for Urologists

February 24th 2015

Jim Feldman, chief innovative officer, Shift Happens, discusses change management for urologists and why it is important for them to have a social media presence.

Dr. Jonathan Henderson Discusses the Professional Need and Business Model for Men's Health Clinics

February 20th 2015

Jonathan Henderson, MD, urologist, Regional Urology, assistant director of clinical research, discusses how men's health clinics should be run by urologists.

Dana Jacoby on How a Group of Physicians Can Become a Successful Medical Group

February 19th 2015

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Bob Asinof on Recruiting Physicians to Private Centers

February 18th 2015

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Radium-223 for Treatment of Prostate Cancer

February 13th 2015

Antiandrogen Resistance With AR-V7 in CRPC

February 13th 2015

Enzalutamide Offers Second Option in Pre-Chemo CRPC

February 13th 2015

Pre-Chemotherapy Abiraterone Acetate in CRPC

February 13th 2015

Integrating CHAARTED Findings Into Prostate Cancer Care

February 13th 2015

CHAARTED Trial Changes Practice in Prostate Cancer

February 13th 2015

ADT in Prostate Cancer: Agonists Versus Antagonists

February 13th 2015

Integrating Molecular Testing Into Urology Practices

February 13th 2015

Biomarkers for Aiding Risk Stratification and Treatment Decisions

February 13th 2015

Follow-up Biomarker Testing in Prostate Cancer

February 13th 2015

Strategies for Using Biomarkers in Prostate Cancer

February 13th 2015

Sequencing VEGFR-Targeted and mTOR-Targeted Therapy in Advanced Renal Cell Carcinoma

February 2nd 2015

With 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.

Dr. Cookson on Ideal Bladder Cancer Biomarkers

January 13th 2015

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Collaboration in Groups Improves Care, Averts Pay Cuts

December 24th 2014

Urologists who are members of LUGPA are doing the right thing by being part of large group practices.

Multiparametric MRI Could Reduce Overdetection and Overtreatment in Prostate Cancer

December 20th 2014

The use of multiparametric MRI in diagnosing and treating prostate cancer was explored in November during a continuing medical education course offered at the annual meeting of LUGPA

Final Thoughts on Improving Prostate Cancer Care

December 17th 2014